These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22046630)

  • 21. Inside HDAC with HDAC inhibitors.
    Bertrand P
    Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HDAC2 deficiency and histone acetylation.
    Ree AH; Folkvord S; Flatmark K
    Nat Genet; 2008 Jul; 40(7):812-3; author reply 813. PubMed ID: 18583969
    [No Abstract]   [Full Text] [Related]  

  • 23. Global analysis of functional relationships between histone point mutations and the effects of histone deacetylase inhibitors.
    Sato L; Noguchi S; Hayashi Y; Sakamoto M; Horikoshi M
    Genes Cells; 2010 Jun; 15(6):553-94. PubMed ID: 20553507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in the discovery of small molecule histone deacetylase inhibitors.
    Remiszewski SW
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):487-99. PubMed ID: 12197307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acetylation of Sirt2 by p300 attenuates its deacetylase activity.
    Han Y; Jin YH; Kim YJ; Kang BY; Choi HJ; Kim DW; Yeo CY; Lee KY
    Biochem Biophys Res Commun; 2008 Oct; 375(4):576-80. PubMed ID: 18722353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting oxidative stress in cancer.
    Lawless MW; O'Byrne KJ; Gray SG
    Expert Opin Ther Targets; 2010 Nov; 14(11):1225-45. PubMed ID: 20942747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. H3K9 acetylation and radial chromatin positioning.
    Strasák L; Bártová E; Harnicarová A; Galiová G; Krejcí J; Kozubek S
    J Cell Physiol; 2009 Jul; 220(1):91-101. PubMed ID: 19248079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.
    Anne-Laurence B; Caroline R; Irina P; Jean-Philippe L
    Subcell Biochem; 2007; 41():263-93. PubMed ID: 17484132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].
    Jiang H; Jia D; Tang B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):52-5. PubMed ID: 20140868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heart failure: the pivotal role of histone deacetylases.
    Hewitson R; Dargan J; Collis D; Green A; Moorjani N; Ohri S; Townsend PA
    Int J Biochem Cell Biol; 2013 Feb; 45(2):448-53. PubMed ID: 23178536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
    Jones P; Altamura S; De Francesco R; Gallinari P; Lahm A; Neddermann P; Rowley M; Serafini S; Steinkühler C
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1814-9. PubMed ID: 18308563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acetylation of histone deacetylase 6 by p300 attenuates its deacetylase activity.
    Han Y; Jeong HM; Jin YH; Kim YJ; Jeong HG; Yeo CY; Lee KY
    Biochem Biophys Res Commun; 2009 May; 383(1):88-92. PubMed ID: 19344692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Assay for inhibitory activity of histone deacetylase].
    Yoshida M
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone deacetylase inhibitors that target tubulin.
    Schemies J; Sippl W; Jung M
    Cancer Lett; 2009 Aug; 280(2):222-32. PubMed ID: 19268440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase and microtubules as targets for the synthesis of releasable conjugate compounds.
    Passarella D; Comi D; Vanossi A; Paganini G; Colombo F; Ferrante L; Zuco V; Danieli B; Zunino F
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6358-63. PubMed ID: 19833515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitors.
    Marks PA; Richon VM; Miller T; Kelly WK
    Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HDACs in skeletal muscle remodeling and neuromuscular disease.
    Simmons BJ; Cohen TJ; Bedlack R; Yao TP
    Handb Exp Pharmacol; 2011; 206():79-101. PubMed ID: 21879447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.